Patents by Inventor John Douglas Davis

John Douglas Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSING, AND METHODS OF USE
    Publication number: 20160355606
    Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
    Type: Application
    Filed: December 28, 2015
    Publication date: December 8, 2016
    Inventors: Yan Wu, Cecilia Pui Chi Chiu, Daniel K. Kirchhofer, Andrew Peterson, Ganesh A. Kolumam, Monica Kong Beltran, Paul Moran, Wei Li, Xanthe Lam, Lin Luis, Ada Hui, Whittemore Tingley, John Douglas Davis, Nageshwar R. Budha
  • ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSING, AND METHODS OF USE
    Publication number: 20130344085
    Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 26, 2013
    Inventors: Yan WU, Cecilia Pui Chi CHIU, Daniel K. KIRCHHOFER, Andrew PETERSON, Ganesh A. KOLUMAM, Monica Kong BELTRAN, Paul MORAN, Wei LI, Xanthe LAM, Lin LUIS, Ada HUI, Whittemore TINGLEY, John Douglas DAVIS, Nageshwar R. BUDHA
  • Pharmaceutical formulations
    Patent number: 7163696
    Abstract: The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941–1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37° C. Formulations according to the invention are suitable for the treatment of BPH.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: January 16, 2007
    Assignee: Pfizer Inc.
    Inventors: John Douglas Davis, Michael John Humphrey, Ross James Macrae, Janet Sarah Smith
  • Pharmaceutical formulations
    Publication number: 20030133978
    Abstract: The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37° C.
    Type: Application
    Filed: October 10, 2002
    Publication date: July 17, 2003
    Inventors: John Douglas Davis, Michael John Humphrey, Ross James Macrae, Janet Sarah Smith